These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16194193)

  • 1. An ideal thrombolytic and antithrombotic agent?
    Matsuo O
    J Thromb Haemost; 2005 Oct; 3(10):2154-5. PubMed ID: 16194193
    [No Abstract]   [Full Text] [Related]  

  • 2. New directions in thrombolytic therapy.
    Toombs CF
    Curr Opin Pharmacol; 2001 Apr; 1(2):164-8. PubMed ID: 11714091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Staphylokinase--a specific plasminogen activator].
    Rozpończyk E; Szemraj J; Malinowski M; Rozpończyk J
    Postepy Biochem; 2006; 52(1):80-6. PubMed ID: 16869305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ideal fibrinolytic: can drug design improve clinical results?
    Van de Werf FJ
    Eur Heart J; 1999 Oct; 20(20):1452-8. PubMed ID: 10493843
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of tenecteplase in peripheral embolic disease.
    Bannerjee AK; Dastidar DG
    Indian Heart J; 2010; 62(4):313-5. PubMed ID: 21280470
    [No Abstract]   [Full Text] [Related]  

  • 6. Fibrin-selective thrombolytic therapy with recombinant staphylokinase.
    Collen D; Vanderschueren S; Van de Werf F
    Haemostasis; 1996 Oct; 26 Suppl 4():294-300. PubMed ID: 8979135
    [No Abstract]   [Full Text] [Related]  

  • 7. [New strategies in the management of venous thromboembolis. International Congress for Vascular Medicine. Graz, Austria, 25-27 June 1998].
    Dtsch Med Wochenschr; 1998 Oct; 123(43 Suppl):1-8. PubMed ID: 9821405
    [No Abstract]   [Full Text] [Related]  

  • 8. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity--a staphylokinase variant. I. In vitro study.
    Szemraj J; Walkowiak B; Kawecka I; Janiszewska G; Buczko W; Bartkowiak J; Chabielska E
    J Thromb Haemost; 2005 Oct; 3(10):2156-65. PubMed ID: 16150047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolytic agents.
    Thompson PL
    Med J Aust; 1994 Jan; 160(1):29-32. PubMed ID: 8271981
    [No Abstract]   [Full Text] [Related]  

  • 10. [New thrombolytic agents].
    Okada K
    Rinsho Byori; 1992 Mar; Suppl 92():115-30. PubMed ID: 1583770
    [No Abstract]   [Full Text] [Related]  

  • 11. Liposomal nanocarriers for plasminogen activators.
    Koudelka S; Mikulik R; Mašek J; Raška M; Turánek Knotigová P; Miller AD; Turánek J
    J Control Release; 2016 Apr; 227():45-57. PubMed ID: 26876783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinolytic agents: mechanisms of activity and pharmacology.
    Lijnen HR; Collen D
    Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of Low-Dose Recombinant Tissue Plasminogen Activator to Treat a Preterm Infant with an Intrauterine Spontaneous Arterial Thromboembolism.
    Demirelli Y; Tekgündüz KŞ; Caner İ; Kara M
    Turk J Haematol; 2015 Dec; 32(4):359-62. PubMed ID: 26377159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents.
    Huber K
    J Thromb Thrombolysis; 2001 May; 11(3):195-202. PubMed ID: 11577257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activation and thrombolysis for ischemic stroke.
    Medcalf RL; Davis SM
    Int J Stroke; 2012 Jul; 7(5):419-25. PubMed ID: 22463085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombolysis in stroke--rush is good but do not forget the pharmacology!].
    Andsberg G; Norrving B
    Lakartidningen; 2013 Feb 20-26; 110(8):423. PubMed ID: 23488443
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug evaluation: alfimeprase, a plasminogen-independent thrombolytic.
    Shah AR; Scher L
    IDrugs; 2007 May; 10(5):329-35. PubMed ID: 17487785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro models for assessing transcranial ultrasound-enhanced thrombolysis.
    Meairs S; Dempfle CE
    Stroke; 2005 May; 36(5):929-30; author reply 930-1. PubMed ID: 15867163
    [No Abstract]   [Full Text] [Related]  

  • 20. [Biochemical, pharmacologic and clinical properties of new thrombolytic agents].
    Gulba DC
    Internist (Berl); 1996 Jun; 37(6):552-66. PubMed ID: 8767988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.